What is Vaxxas?
Headquartered in Brisbane, Australia, Vaxxas is pioneering a paradigm shift in immunization through its HD-MAP platform. Unlike traditional needle-and-syringe methods, the HD-MAP technology targets immune cells just beneath the skin, facilitating robust immune responses with smaller doses. This innovation is compatible with various vaccine modalities, including mRNA and protein subunits, offering a universal solution for global health challenges. By enabling self-administration and reducing the reliance on complex cold-chain infrastructure, Vaxxas is effectively lowering barriers to vaccine distribution. The company's clinical data, spanning over 750 participants, validates the safety and efficacy of its approach, marking it as a high-potential player in the multibillion-dollar vaccine sector.
How much funding has Vaxxas raised?
Vaxxas has raised a total of $124.6M across 5 funding rounds:
Series A
$15M
Series B
$20M
Grant
$8.2M
Other Financing Round
$23M
Series D
$58.4M
Series A (2011): $15M, investors not publicly disclosed
Series B (2015): $20M led by Medical Research Commercialisation Fund (MRCF), Healthcare Ventures, Brandon Capital, and OneVentures
Grant (2022): $8.2M supported by Australian Government
Other Financing Round (2022): $23M featuring OneVentures and Uniquest
Series D (2025): $58.4M backed by OneVentures, Brandon Capital, LGT Crestone Wealth Management, and Sprim Global Investments
Key Investors in Vaxxas
Brandon Capital
Brandon Capital Partners specializes in seed and venture capital investments in the biomedical sector, focusing on life science companies that aim to enhance patient outcomes through innovative medical solutions.
LGT Crestone Wealth Management
LGT Wealth Management Australia specializes in providing tailored private wealth management and investment solutions for high-net-worth and ultra high-net-worth clients, combining local relationships with global expertise.
Sprim Global Investments
SPRIM Global Investments focuses on investing in companies that enhance R&D capabilities in the life sciences sector, providing support across various clinical stages of drug and device development.
What's next for Vaxxas?
With the recent influx of capital, Vaxxas is strategically positioned to accelerate its commercialization roadmap. The focus will likely shift toward scaling high-volume manufacturing to meet anticipated global demand while continuing to navigate the regulatory pathways for its lead candidates. As the company moves beyond clinical validation, the emphasis will be on establishing strategic partnerships to integrate the HD-MAP platform into existing public health frameworks. The backing from seasoned life science investors provides not only the necessary liquidity but also the operational expertise required to navigate the complexities of the global biotechnology landscape, ensuring that Vaxxas remains at the forefront of medical delivery innovation.
See full Vaxxas company page
